Tikagrelor: Perbedaan antara revisi

Jelajahi riwayat secara interaktif

← Revisi sebelumnya

Konten dihapus Konten ditambahkan

VisualTeks wiki

Revisi per 28 April 2024 22.26 sunting Muhammad Anas Sidik (bicara \| kontrib) 24.329 suntingan Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan ← Revisi sebelumnya		Revisi terkini sejak 24 Agustus 2024 14.47 sunting balikkan Hysocc (bicara \| kontrib) Pengguna terkonfirmasi, Peninjau 63.556 suntingan k Removing from Category:Antiplatelet using Cat-a-lot Tag: halaman dengan galat kutipan
(5 revisi perantara oleh 2 pengguna tidak ditampilkan)
Baris 1: {{Infobox drug ~~{{Dead end\|date=Februari 2023}}~~ \| Verifiedfields = changed \| Watchedfields = changed \| verifiedrevid = 443228756 \| image = Ticagrelor.svg \| width = 200 \| alt = \| image2 = Ticagrelor ball-and-stick animation.gif \| alt2 = \| caption = <!-- Clinical data --> ~~'''Tikagrelor''' merupakan obat penghambat agregrasi trombosit dari golongan antagonist reseptor P2Y12.~~ \| pronounce = \| tradename = Briclot, Brilinta, Brilique, dll \| Drugs.com = {{drugs.com\|monograph\|ticagrelor}} \| MedlinePlus = a611050 \| DailyMedID = Ticagrelor \| pregnancy_AU = B1 \| pregnancy_AU_comment = <ref>{{cite web \| title=Updates to the Prescribing Medicines in Pregnancy database \| website=Therapeutic Goods Administration (TGA) \| date=12 May 2022 \| url=https://www.tga.gov.au/resources/resource/guidance/updates-prescribing-medicines-pregnancy-database \| access-date=13 May 2022}}</ref> \| pregnancy_category = \| routes_of_administration = Oral \| class = \| ATC_prefix = B01 \| ATC_suffix = AC24 \| ATC_supplemental = <!-- Legal status --> \| legal_AU = S4 \| legal_AU_comment = <ref>{{cite web \| title=Ticalor; Blooms The Chemist Ticagrelor; Apo-Ticagrelor; Ticagrelor Arx (Accelagen Pty Ltd) \| website=Therapeutic Goods Administration (TGA) \| date=11 November 2022 \| url=https://www.tga.gov.au/resources/prescription-medicines-registrations/ticalor-blooms-chemist-ticagrelor-apo-ticagrelor-ticagrelor-arx-accelagen-pty-ltd \| access-date=9 April 2023}}</ref> \| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F --> \| legal_BR_comment = \| legal_CA = Rx-only \| legal_CA_comment = <ref>{{cite web \| title=Product monograph brand safety updates \| website=Health Canada \| date=February 2024 \| url=https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database/label-safety-assessment-update/product-monograph-brand-safety-updates.html \| access-date=24 March 2024}}</ref> \| legal_DE = <!-- Anlage I, II, III or Unscheduled --> \| legal_DE_comment = \| legal_NZ = <!-- Class A, B, C --> \| legal_NZ_comment = \| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --> \| legal_UK_comment = \| legal_US = Rx-only \| legal_US_comment = <ref name="Brilinta FDA label">{{cite web \| title=Brilinta- ticagrelor tablet \| website=DailyMed \| date=10 August 2021 \| url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7b3f443-e83d-4bf2-0e96-023448fed9a8 \| access-date=19 May 2022}}</ref> \| legal_EU = Rx-only \| legal_EU_comment = <ref name="Brilique EPAR">{{cite web \| title=Brilique EPAR \| website=European Medicines Agency \| date=17 September 2018 \| url=https://www.ema.europa.eu/en/medicines/human/EPAR/brilique \| access-date=18 May 2022}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> \| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> \| legal_UN_comment = \| legal_status = <!-- For countries not listed above --> <!-- Pharmacokinetic data --> \| bioavailability = 36% \| protein_bound = >99.7% \| metabolism = [[Hati]] (CYP3A4) \| metabolites = \| onset = \| elimination_half-life = 7 jam (tikagrelor), 8.5 jam metabolit aktif AR-C124910XX) \| duration_of_action = \| excretion = [[Saluran empedu]] <!-- Identifiers --> \| CAS_number_Ref = {{cascite\|correct\|??}} \| CAS_number = 274693-27-5 \| PubChem = 9871419 \| IUPHAR_ligand = 1765 \| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}} \| DrugBank = DB08816 \| ChemSpiderID_Ref = {{chemspidercite\|changed\|chemspider}} \| ChemSpiderID = 8047109 \| UNII_Ref = {{fdacite\|correct\|FDA}} \| UNII = GLH0314RVC \| KEGG_Ref = {{keggcite\|correct\|kegg}} \| KEGG = D09017 \| ChEBI = \| ChEMBL_Ref = {{ebicite\|changed\|EBI}} \| ChEMBL = 398435 \| NIAID_ChemDB = \| PDB_ligand = \| synonyms = AZD-6140 <!-- Chemical and physical data --> \| IUPAC_name = (1''S'',2''S'',3''R'',5''S'')-3-[7-[(1''R'',2''S'')-2-(3,4-Difluorofenil)siklopropilamino]-5-(propiltio)- 3''H''-[1,2,3]triazolo[4,5-''d'']pirimidin-3-il]-5-(2-hidroksietoksi)siklopentana-1,2-diol \| C=23 \| H=28 \| F=2 \| N=6 \| O=4 \| S=1 \| SMILES = CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1 \| StdInChI_Ref = {{stdinchicite\|changed\|chemspider}} \| StdInChI = 1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1 \| StdInChI_comment = \| StdInChIKey_Ref = {{stdinchicite\|changed\|chemspider}} \| StdInChIKey = OEKWJQXRCDYSHL-FNOIDJSQSA-N \| density = \| density_notes = \| melting_point = \| melting_high = \| melting_notes = \| boiling_point = \| boiling_notes = \| solubility = \| sol_units = \| specific_rotation = }} '''Tikagrelor''' adalah obat yang digunakan untuk pencegahan [[strok]], [[serangan jantung]] dan kejadian lain pada penderita [[sindrom koroner akut]], yaitu masalah suplai darah di [[arteri koroner]]. Ia bertindak sebagai [[antiplatelet]] dengan memusuhi reseptor P2Y<sub>12</sub>.<ref>{{cite journal \| vauthors = Jacobson KA, Boeynaems JM \| title = P2Y nucleotide receptors: promise of therapeutic applications \| journal = Drug Discovery Today \| volume = 15 \| issue = 13–14 \| pages = 570–578 \| date = July 2010 \| pmid = 20594935 \| pmc = 2920619 \| doi = 10.1016/j.drudis.2010.05.011 }}</ref> Obat tersebut diproduksi oleh [[AstraZeneca]]. Efek samping yang paling umum termasuk [[dispnea]] (kesulitan bernapas), pendarahan, dan peningkatan kadar [[asam urat]] dalam darah.<ref name="Brilique EPAR" /> Obat ini disetujui untuk penggunaan medis di Uni Eropa pada bulan Desember 2010,<ref name="Brilique EPAR" /><ref name="EPAR Brilique">{{cite web\|url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001241/WC500100492.pdf\|title=Assessment Report for Brilique\|publisher=[[European Medicines Agency]]\|date=January 2011}}</ref><ref>[http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002303/human_med_001399.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125 European Public Assessment Report Possia]</ref> dan di Amerika Serikat pada bulan Juli 2011.<ref name="Brilinta FDA label" /><ref>{{cite press release \|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm263964.htm\|archive-url=https://wayback.archive-it.org/7993/20170112024017/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm263964.htm\|url-status=dead\|archive-date=12 January 2017\|title=FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes\|publisher=U.S. [[Food and Drug Administration]] (FDA)\|date=20 July 2011}}</ref><ref>{{cite web \| title=Drug Approval Package: Brilinta (ticagrelor) NDA #022433 \| publisher=U.S. [[Food and Drug Administration]] (FDA) \| date=22 August 2011 \| url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000TOC.cfm \| access-date=22 May 2021}}</ref> == Fungsi Klinis == Penggunaan ~~ticagrelor~~tikagrelor diindikasikan untuk mencegah kejadian trombosis pada pasien dengan infark miokard. Berdasarkan studi PLATO, penggunaan ~~ticagrelor~~tikagrelor pada pasien dengan sindrom koroner akut dapat menurunkan laju kematian tanpa peningkatan risiko perdarahan dibandingkan dengan ~~clopidogrel~~[[klopidogrel]].<ref>{{cite web\|url=http://kardioipdrscm.com/6763/artikel/ticagrelor-harapan-baru-dalam-prevensi-sekunder-pada-pasien-infark-miokard/.do\|title=Ticagrelor, Harapan Baru Dalam Prevensi Sekunder Pada Pasien Infark Miokard\|publisher=Kardioipdrscm.com\|first=S\|last=Salim\|date=15 February 2015}}{{Pranala mati\|date=Mei 2021 \|bot=InternetArchiveBot \|fix-attempted=yes }}</ref> == Referensi == {{reflist}} [[Kategori:~~Obat~~Penghambat reseptor difosfat adenosin]] [[Kategori:~~Antiplatelet~~Penghambat CYP3A4]] [[Kategori:Triazolopirimidina]] [[Kategori:Fluoroarena]] [[Kategori:Siklopropana]] [[Kategori:Senyawa propil]] [[Kategori:Obat yang dikembangkan oleh AstraZeneca]]